It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ultraviolet radiation (UVR) damages the dermis and fibroblasts; and increases melanoma incidence. Fibroblasts and their matrix contribute to cancer, so we studied how UVR modifies dermal fibroblast function, the extracellular matrix (ECM) and melanoma invasion. We confirmed UVR-damaged fibroblasts persistently upregulate collagen-cleaving matrix metalloprotein-1 (MMP1) expression, reducing local collagen (COL1A1), and COL1A1 degradation by MMP1 decreased melanoma invasion. Conversely, inhibiting ECM degradation and MMP1 expression restored melanoma invasion. Primary cutaneous melanomas of aged humans show more cancer cells invade as single cells at the invasive front of melanomas expressing and depositing more collagen, and collagen and single melanoma cell invasion are robust predictors of poor melanoma-specific survival. Thus, primary melanomas arising over collagen-degraded skin are less invasive, and reduced invasion improves survival. However, melanoma-associated fibroblasts can restore invasion by increasing collagen synthesis. Finally, high COL1A1 gene expression is a biomarker of poor outcome across a range of primary cancers.
Ultraviolet radiation (UVR) increases melanoma incidence. Here, the authors report that UVR-damaged dermal fibroblasts upregulate MMP1 to degrade collagen which inhibits melanoma invasion and that aged primary melanomas in skin with degraded collagen have a better prognosis, while new collagen synthesis restores invasion and leads to death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Kay, Emily 4 ; Gurung Shilpa 1 ; Earnshaw, Charles H 1
; Roeck Katharina 1 ; Craig, Sarah 1
; Traves Víctor 5 ; Krutmann Jean 6
; Muller, Patricia 7 ; Motta, Luisa 8 ; Zanivan Sara 4
; Malliri Angeliki 3
; Furney, Simon J 9
; Nagore Eduardo 10
; Amaya, Virós 1
1 The University of Manchester, Skin Cancer and Ageing Lab, Cancer Research UK Manchester Institute, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
2 Aix-Marseille University, Department of Dermatology and Skin Cancers, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
3 The University of Manchester, Alderley Park, Cell Signalling Group, Cancer Research UK Manchester Institute, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
4 University of Glasgow, Institute of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); CRUK Beatson Institute, Glasgow, UK (GRID:grid.8756.c)
5 Institut Valencià Oncologia, Department of Dermatology, Valencia, Spain (GRID:grid.5379.8)
6 IUF – Leibniz Research Institute of Environmental Medicine, Düsseldorf, Germany (GRID:grid.435557.5) (ISNI:0000 0004 0518 6318); Heinrich-Heine-University, Medical Faculty, Düsseldorf, Germany (GRID:grid.411327.2) (ISNI:0000 0001 2176 9917)
7 The University of Manchester, Tumour Suppressors Lab, Cancer Research UK Manchester Institute, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
8 The University of Manchester, Department of Histopathology, Salford Royal NHS Foundation Trust, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
9 Royal College of Surgeons in, Genomic Oncology Research Group, Department of Physiology and Medical Physics, Dublin, Ireland (GRID:grid.4912.e) (ISNI:0000 0004 0488 7120); Royal College of Surgeons in Ireland Dublin, Centre for Systems Medicine, Dublin, Ireland (GRID:grid.4912.e) (ISNI:0000 0004 0488 7120)
10 Institut Valencià Oncologia, Department of Dermatology, Valencia, Spain (GRID:grid.4912.e)




